Skip to main content
SpringerLink
Log in

Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma

  • original report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Objectives

This study aimed to investigate the clinical characteristics and prognostic impact of 1q21 gain in patients with newly diagnosed multiple myeloma (MM).

Methods

This was a retrospective study of 197 patients with newly diagnosed MM. Fluorescence in situ hybridization was performed to detect six cytogenetic abnormalities: gain(1q21), del(17p), del(13q14), t(4;14), t(14;16), and t(11;14).

Results

We showed that 57.8% of patients with MM had 1q21 gain. The patients with 1q21 gain had lower IgM (0.39 vs 1.14 g/L, P = 0.037) and higher platelet count (177.62109/l vs 148.29109/l, P = 0.018) than those without 1q21 gain, and were more likely to be accompanied by del(13q14) (P < 0.001) or t(4;14) (P = 0.017).

Conclusions

We showed that 1q21 gain was associated with del(13q14) and t(4;14) increase, but it had no effect on prognosis of patients with newly diagnosed MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225–36.

    Article  Google Scholar 

  2. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, et al. Revised international staging system for multiple myeloma: a report from International MYELOMA working group. J Clin Oncol. 2015;33(26):2863–9.

    Article  CAS  Google Scholar 

  3. Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100–13.

    Article  CAS  Google Scholar 

  4. Byun JM, Dong-Yeop S, Junshik H, et al. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med. 2018;7(3):831–41.

    Article  CAS  Google Scholar 

  5. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–40.

    Article  CAS  Google Scholar 

  6. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosom Cancer. 2005;44(2):194–203.

    Article  CAS  Google Scholar 

  7. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defifined unique subset of patients. Blood. 2002;99:3735–41.

    Article  CAS  Google Scholar 

  8. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–9.

    Article  CAS  Google Scholar 

  9. Chiecchio L, Protheroe RKM, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610–7.

    Article  CAS  Google Scholar 

  10. Decaux O, Lodé L, Minvielle S, et al. Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival. Rev Med Interne. 2007;28:677–81.

    Article  CAS  Google Scholar 

  11. Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–52.

    Article  Google Scholar 

  12. Smol T, Dufour A, Tricot S, et al. Combination of t(4;14),del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma. Mol Cytogenet. 2017;10:26.

    Article  Google Scholar 

  13. Chng WJ, Dispenzieri A, Chim C‑S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–77.

    Article  CAS  Google Scholar 

  14. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360–76. https://doi.org/10.1016/j.mayocp.2013.01.019.

    Article  PubMed  Google Scholar 

  15. Nemec P, Zemanova Z, Greslikova H, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548–54.

    Article  CAS  Google Scholar 

  16. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489–95.

    Article  CAS  Google Scholar 

  17. Bang SM, Kim YR, Cho HI, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168(2):124–32.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Cathel Kerr, BSc, PhD, from Liwen Bianji (Edanz) (www.liwenbianji.cn/) for editing the English text of a draft of this manuscript.

Funding

This research did not receive any specific grant from funding agencies.

Author information

Authors and Affiliations

  1. Central Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui, 230001, Hefei, China

    Xiao Xiao, Xinchen Fang & Zhu Huaiping

  2. Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui, 230001, Hefei, China

    Wen Yao

Authors
  1. Xiao Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinchen Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wen Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhu Huaiping
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xinchen Fang or Wen Yao.

Ethics declarations

Conflict of interest

X. Xiao, X. Fang, W. Yao and Z. Huaiping declare that they have no potential conflicts of interest. The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiao, X., Fang, X., Yao, W. et al. Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma. memo 15, 90–93 (2022). https://doi.org/10.1007/s12254-021-00774-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-021-00774-6

Keywords

Search

Navigation